ArticlePsychopharmacology2021
Fluvoxamine, melatonin and COVID-19.
Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.The Lancet. Global health · 2022Trial
- Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.Life (Basel, Switzerland) · 2025Review
- Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data.The Lancet regional health. Western Pacific · 2023Article
- The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis.Health science reports · 2022Article
- Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.CNS drugs · 2022Review
- Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder.Journal of psychiatric research · 2022Review
- Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.British journal of clinical pharmacology · 2022Article
- Mechanisms of action of fluvoxamine for COVID-19: a historical review.Molecular psychiatry · 2022Review
- Overview of sleep management during COVID-19.Sleep medicine · 2022Review
- Sleep Dysfunction in COVID-19 Patients: Prevalence, Risk Factors, Mechanisms, and Management.Journal of personalized medicine · 2021Review
- Recent advances in management of COVID-19: A review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.Expert opinion on therapeutic targets · 2021Review
- Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2021Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.